Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company’s fiscal third quarter ended January 31, 2012.
Net sales for the three months ended January 31, 2012 were $55,625,000, an increase of $5,925,000 or 12% compared to the net sales of $49,700,000, for the three months ended January 31, 2011.
Net sales for generic pharmaceuticals for the three months ended January 31, 2012 were $47,541,000, an increase of $6,995,000 or 17%, compared to sales of $40,546,000 for the respective prior fiscal period. The increase was primarily due to stronger sales of Fluticasone Propionate nasal spray. Sales of Fluticasone Propionate increased to $21,800,000 from $17,900,000 in the comparable quarter as the Company sold more units at a lower average price. The Company also benefited from sales of Gabapentin oral solution, launched in February 2011, Ranitidine oral solution, launched in May 2011, Levofloxacin oral solution, launched in June 2011 and Lidocaine sterile jelly, launched in September 2011. Increased sales of the Company’s Clobetasol line of topical products and Buprenorphine sublingual tablet also contributed to the results.
ECR Pharmaceuticals contributed $4,347,000 to sales in the current period, a decrease of $1,134,000 or 21%, compared to sales of $5,481,000 for the respective fiscal 2011 period. The decrease was primarily due to the discontinuation of the extended release versions in the Lodrane
line of antihistamines. Increased sales of recently acquired products, including TussiCaps
, partially offset the decrease in sales for the quarter.
Net sales for the Health Care Products division, which markets the Company’s OTC branded products, increased slightly to $3,737,000 compared to $3,673,000 reported for the same period last year.
Cost of goods sold increased to $24,889,000 or 45% of net sales, for the three months ended January 31, 2012 from $21,067,000, or 42% of net sales, for the three months ended January 31, 2011. The increase in cost of goods sold as a percentage of net sales is primarily due to lower sales in the high margin ECR Pharmaceuticals subsidiary as well as pricing declines for both Fluticasone Propionate nasal spray and Dorzolamide ophthalmic products.